- Clone:
- REAL753
- Type of antibody:
- Releasable fluorochromes, Primary antibodies, Recombinant antibodies
- Applications:
- MICS, IF, IHC Glossary
- Select a conjugate:
Related products for Cytokeratin 20 Antibody, anti-human, REAdye_lease™
A
B
A
B
A
B
Clone REAL753 is an antibody fragment derived from the full Cytokeratin 20 antibody molecule. It displays no binding to Fc receptors. The recombinantly engineered antibody fragments are multimerized to form the REAdye_lease Complex to bind markers with high avidity.
Clone REAL753 recognizes the Cytokeratin 20 protein, also known as Keratin 20 or CK20, that belongs to the intermediate filament family. It plays a significant role in maintaining keratin filament organization in intestinal epithelia. Cytokeratin 20 is expressed mostly in the intestinal epithelium such as in colonic mucosa and Merkel cells and functions as imunohistology diagnostic marker for adenocarcinoma arising from epithelia.
For removal of REAdye_lease fluorochromes for optional relabeling with different fluorochrome-conjugated REAdye_lease antibodies use the REAlease Support Kit (130-120-675).
KRT20, Keratin type I cytoskeletal 20, CK-20, Keratin-20, K20, Protein IT, CK20, Keratin 20
Technical specifications
To access a Certificate of Analysis (CoA) follow the link below and enter the specific lot of your product.
Should you wish to request additional documentation, such as a Safety Data Sheet (SDS) in other languages than English or Swedish, an SDS-replacement document, or a Certificate of Origin (CoO), please direct your inquiry to your local technical support team.
- Chu, P. et al. (2000) Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod. Pathol. 13 (9): 962-972
- Moll, R. et al. (1992) Cytokeratin 20 in human carcinomas. A new histodiagnostic marker detected by monoclonal antibodies. Am. J. Pathol. 140 (2): 427-447
- Moll, R. et al. (1993) The human gene encoding cytokeratin 20 and its expression during fetal development and in gastrointestinal carcinomas. Differentiation 53 (2): 75-93
You have previously chosen International as your location.
What do you want to do?